CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro.
Patrick N SongAmeer MansurKari J DuggerTessa R DavisGrant HowardThomas E YankeelovAnna G SoracePublished in: Cancer cell international (2020)
The presence of T-cells significantly increases the efficacy of targeted therapies and suggests trastuzumab may trigger immune mediated cytotoxicity. Increased TNF-α receptor expression suggest cytokines may interact with trastuzumab to create a state of enhanced response to therapy in HER2 + breast cancer, which has potential to reducing tumor burden.